We would love to hear your thoughts about our site and services, please take our survey here.
What do we expect?
My guess is they cant do a placing while the SP is plummeting?
As for a buy out, why would an offer be made with no data yet?
Thoughts
I have faith in the science but NOT the management, whoever did the deal needs to go, or that could been their plan, look at the route MONO took , Sierra bought for peanuts, and racked it in for themselves. Management pocket being lined? (GSK at it again???) Pharma isn't as Rosie as people imagine! GSK know who Sareum are.
10 out 10 mice Blah Blah Blah, I want back in, but only once we know how they are going to get themselves out this cluster muck
GLA however this ends up, remember its only money ;)
most buys below 1k
i offloaded my lot (140+k shares) earlier today.
did serious thinking last night, something really stinks, so i decided to sell up! was already on a free ride, but still a kick in *******s watching the collapse, only way out for sareum is further financing, which once done (hopefully) i will then look to invest again. i believe in the science but they just cant manage the business!
have been burnt to many times previously...
glalth's and hope this does turn a corner soon.
Just stumbled on this , Page 2
SRA7307-01 / CANC 30500
SRA737-02 / CANC 30498
https://thamesvalleycanceralliance.nhs.uk/wp-content/uploads/2023/09/Trials-on-Aria-September-a-2023.pdf
GLALTH's ;)
For those who may have missed this.. (I for 1 did!)
https://sareum.com/wp-content/uploads/2023/08/Sareum-Company-July-2023.pdf
• Sareum/ CPF evaluating potential licensing opportunities
well then, its NOT just CPF steering 737's path...
Summary
• Sareum is a clinical stage small molecule drug development company developing next
generation kinase inhibitors for autoimmune disease and cancer
• JAK cell signalling family (TYK2, JAK1 JAK2, JAK3) is an area of growing commercial focus
with good scientific validation
• Initiated a Phase 1a study in Australia for its lead programme SDC-1801, a dual
TYK2/JAK1 inhibitor
• Expecting to report key clinical trial milestones throughout 2023 and 2024
urrmm, im waiting for trial results, and bet a deals done before then ;)
Very sad news, RIP T2, condolences to all your family.
Will be truly missed on this board.
Legend in his own right
Hoping his Sareum shares are still in good hands Libarhen, believe he had quite a few… golden tickets could be a fleet Yachts soon ;)
God bless, and good luck x
Https://www.anzctr.org.au/TrialSearch.aspx#&&searchTxt=SDC-1801.
Ethics status: Approved
Prospectively registered
Anticipated date of first participant enrolment
04 June 2023
Have a good weekend all
Thank you for sharing findings HBD, really appreciated time and effort, now lets get back to business Sareum! deliver info to your faithful shareholders.... wish T2 could witness the developments but who knows what's occurred there?.
Ignition for Tuesday, if the markets asleep, I for one will be loading my 2023 ISA allowance into Sareum, can see them over £4 before 2024 (just need to go through my piggy banks!)
GLALTH's and enjoy the rest b/h weekend ;)
https://ir.biohaven.com/news-releases/news-release-details/biohaven-acquires-exclusive-license-oral-brain-penetrant-dual
Biohaven anticipates advancing the agent into a Phase 1 study in 2023
http://www.sareum.com/files/4016/7362/2938/Sareum_Company_Jan_23.pdf
For those who may have missed it..
https://www.edisongroup.com/wp-content/uploads/2023/01/Oncology_ABCs_Thematic_Part4_040123.pdf
Interesting reading..
http://www.sareum.com/news/events/
let's see what evolves
https://www.biopharmadive.com/news/tyk2-inhibitors-jak-protein-startups-biotech/633635/
Well, if they can raise these sort figures as new startups, think rocket fuel comes to mind for our wee Sareum's molecules ;)
https://www.marketwatch.com/press-release/usd-14980-billion-global-anti-inflammatory-biologics-market-during-2021-2028-fortune-business-insights-2022-08-05?mod=search_headline
I'm holding till the well tuned lady sings ;)
Looks like another 4 inhibitors stalled..
Pipeline update:
Decided to move forward with GLPG3667 (TYK2 inhibitor) in dermatomyositis with the aim to start a Phase 2 study before year-end
Discontinued development of 4 early-stage programs as part of ongoing scientific and strategic exercise: GLPG3121, a local release formulation JAK1/TYK2 inhibitor with potential in inflammatory diseases; GLPG0555, a JAK1 inhibitor evaluated in osteoarthritis; GLPG4586, a compound with undisclosed mode of action directed toward fibrosis; and GLPG4716, a chitinase inhibitor directed toward idiopathic pulmonary fibrosis
https://www.glpg.com/press-release/3657/first-key-steps-in-pipeline-rebuild-and-strong-commercial-progress-in-h1-2022
great RNS and great postings et all researchers. Its coming home guys ;)
I'm feeling it in me waters, and maybe red wines contributing ..
share price is what it is, once hefty trades start appearing, that's when balls of steel will be required, 10, 20, 30p well set your own goals
in mean time, any of our pharma wizzes looking for a job around Manchester ;)
https://uk.indeed.com/Leading-Pharmaceutical-Company-jobs-in-Greater-Manchester?vjk=20734017373a48b5&advn=5767036102460837
GLALTH's